NIT became a participant of the United Nations Global Compact initiative since September 2022. NIT accepts and will take actions to support the Ten Principles of the UN Global Compact and the Sustainable Development Goals (SDGs).
We strive to always be humble and show respect towards others. This means that we celebrate their successes and empathize with their failures. We appreciate each other’s similarities as well as differences and meet others where they are. Respect is the ruling value.
At the core of our values is hard work and dedication. Through an inner desire to be better, we strive to cultivate and nurture self-motivation in ourselves and in others around us every single day. Positivity begets positivity.
Being responsible for our thoughts and actions is at the heart of who we are. We take responsibility seriously. We hold ourselves and our business partners to a very high standard.
(As of 2022)
BOD Class | Name | Title | R&R | Experiences | Term |
---|---|---|---|---|---|
Class I | Jung Won Woo | Non-Executive Director (Registered/Part-time) |
Non-Executive Director |
(Current) Genexine, Inc. President, R&D (Former) Genexine, Inc. Head of Research Institute |
2021-03-31~ 2023-03-31 |
Class I | Jin-Hyoung Kang | Independent Director (Registered/Part-time) |
Independent Director |
(Current) Seoul St.Mary's Hospital, The Catholic University of Korea, Professor (Former) Gangnam St.Mary's Hospital, The Catholic University of Korea, Associate Professor |
2021-03-31~ 2023-03-31 |
Class II | Byoung Jo Kang | Independent Director (Registered/Part-time) |
Independent Director |
(Current) B.J Kang Law.PLC CEO (Former) Arlington International Tax Firm Flott & Co. Attorney |
2021-03-31~ 2024-03-31 |
Class III | Se Hwan Yang | Executive Director (Registered/Full-time) |
President (CEO) |
(Current) NeoImmuneTech, Inc. CEO (Former) Genexine, Inc. Head of Research Institute and Business Division |
2022-03-31~ 2025-03-31 |
Class III | Soo-Hyoung Kang | Independent Director (Registered/Part-time) |
Independent Director |
(Current) Aimed Bio Inc. Advisor (Former) Aimed Bio Inc. CEO |
2022-03-31~ 2025-03-31 |
In order to secure the independence of the company’s management, the company has minimized the number of directors designated by the largest stockholder to one (1). Also, transactions between the company and the largest stockholder could be considered as interested transactions under the Delaware General Corporation Law, and as such, the director designated by the largest stockholder is recused with respect to any portion of the board meeting during which any interested transaction is discussed, considered, voted, or adopted. Currently, Genexine, Inc. is the largest stockholder, and Jung Won Woo is the director designated by Genexine, Inc. All other directors, including three outside directors, have no special interest in Genexine, Inc.
Round | Date | Agenda | Result | Attended/All | Note |
---|---|---|---|---|---|
21-01 | Jan. 04, 21 | 1) Approval of Chief Financial Officer (CFO) bonus | Approved | 6/6 (2/2) |
- |
21-02 | Jan. 06, 21 | 1) Issuance of IPO stock and additional stock issuance within a maximum of 5% of IPO stock 2) Conclusion of acquisition contract |
Approved | 6/6 (2/2) |
- |
21-03 | Jan. 20, 21 | 1) Approval of conclusion of Chief Operating Officer (COO) employee contract | Approved | 6/6 (2/2) |
- |
21-04 | Jan. 29, 21 | 1) Convenience of general stockholders’ meeting and set date of convening general meeting of stockholders | Approved | 6/6 (2/2) |
- |
21-05 | Feb. 16, 21 | 1) Approval of appointment of Chief Scientific Officer (CSO) 2) Approval of signing of CFO employment contract 3) Confirmation of joint research contract with YBL |
Approved | 6/6 (2/2) |
- |
21-06 | Mar. 08, 21 |
1) Approval of consolidated and separate financial statements for 2020 2) Approval of signing of employment for Chief Executive Officer (CEO) 3) Approval of incentive rules |
Approved | 6/6 (2/2) |
- |
21-07 | Mar. 16, 21 |
1) Approval of grant of stock option 2) Approval of the agenda at the regular general meeting of stockholders |
Approved | 6/6 (2/2) |
- |
21-08 | May. 27, 21 |
1) Approval of signing of employment contract for Chief Business Officer (CBO) 2) Approval of changes to the operating regulations of the BOD 3) Approval of signing an agreement on the succession of the lessee’s status in relation to the sub-lease contract of the research institute affiliated with the company |
Approved | 5/5 (3/3) |
- |
21-09 | Jun. 04, 21 | Approval of cancellation of grant of stock option | Approved | 5/5 (3/3) |
- |
21-10 | Jun. 26, 21 | Approval of cancellation of grant of stock option | Approved | 5/5 (3/3) |
- |
21-11 | Jul. 26, 21 | Approval of signing a contract area change agreement with Genexine Inc. related to the sub-lending contract of the research institute affiliated with the company | Approved | 5/5 (3/3) |
- |
21-12 | Jul. 29, 21 |
1) Approval of cancellation of grant of stock option 2) Changes in stakeholder transaction rules 3) Approval of annual limit on stakeholder transactions 4) Approval of changes to the operating regulations of the board of directors 5) Target bonus payment and Chief Clinical Officer (CCO) appointment according to Dr. Jing (“Jean”) Fan’s one-year evaluation |
Approved | 5/5 (3/3) |
- |
21-13 | Aug. 17, 21 | Approval of the Chief Business Officer (CBO) to set goals for 2021-2022 | Approved | 5/5 (3/3) |
- |
21-14 | Sep. 28, 21 | 1) Approval of stock option exercise guidelines 2) Approval of stock option grant |
Approved | 5/5 (3/3) |
- |
21-15 | Dec. 15, 21 | Establishment of the base date for the 8th regular general meeting of stockholders | Approved | 3/5 (3/3) |
- |
21-16 | Dec. 21, 21 |
1) Approval of transfer of address of subsidiaries 2) Approval of the establishment of internal accounting management regulations 3) Approval of loans to executives and employees 4) Approval of establishment of contract approval regulations and signing authority regulations |
Approved | 5/5 (3/3) |
- |
22-01 | Feb. 15, 22 |
1) Approval of fiscal year 2021 financial statements and business reports 2) Appointment and delegation of external auditors 3) Convocation of a regular general meeting of stockholders 4) Cancellation of grant of stock options |
Approved | 5/5 (3/3) |
- |
22-02 | Feb. 15, 22 | Approval of changes to the COO, CSO, and CFO employment contract | Approved | 5/5 (3/3) |
- |
NeoImmuneTech provides this link as a courtesy and does not control the content of the site you are about to enter.
Do you wish to continue?